Skip to content

Modeling sarcopenic obesity to advance healthy weight loss therapies

  • Barbora Krajnikova

Background & aim: Incretin-based therapies have revolutionized obesity treatment by substantially reducing body weight and fat mass, yet are associated with a disproportionate loss of lean mass compared with traditional weight-loss interventions. Despite the great interest in the matter, primary…

Read more

Metabolic effects of survodutide in DIO mice at thermoneutrality

  • Allison Butt

Background & aim: Survodutide is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), currently in clinical development for obesity and related metabolic disorders. By concurrently enhancing GCGR and GLP1R signaling, survodutide offers a synergistic approach…

Read more
Back To Top